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Abstract:  
Some repeats of three or more nucleotides in tandem, which are present in a gene or in its 
vicinity, tend to increase in number and for this reason are called dynamic mutations. These 
triplet repeats are unstable and can expand from one generation to the next. According to 
the expansion size, an unaffected individual can carry a pre-mutation that will expand 
through generations leading to the development of triplet repeat expansion diseases. The 
increase in the number of repeats over time leads to earlier development and increased 
severity of symptoms in affected individuals in successive generations. Although there is still 
no treatment for this type of disease, several strategies are under investigation. Here, we 
describe treatment approaches for triplet repeat expansion diseases that have been 
developed over recent years, using DNA or RNA molecules as targets. Some of these 
strategies have the potential for future use in gene therapy for trinucleotide repeat 
disorders. 
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1. Introduction 
All eukaryotic and prokaryotic genomes contain a certain number of repetitive sequences that 
can vary in length and repetitive levels similar to long repeats and satellite DNA [1-4]. Overall, 30% 
of the human genome consists of repetitive DNA sequences [5]. 
The presence of trinucleotide repeats (microsatellites), also known as tandem repeat 
sequences, that are responsible for the development of diseases was identified as a novel type of 
mutation in the early 1990s [6]. This type of repetitive sequence is susceptible a high frequency of 
mutations in all genomes [2, 7]. 
Diverse hereditary neurological disorders are caused by expansion of unstable triplet repeats 
[8]. Trinucleotide repeat expansions have been identified as the cause of approximately 20 
neurologic and neuromuscular diseases, although the mechanisms underlying their development 
remain to be elucidated [5, 9]. Examples of this type of disease include myotonic dystrophy (DM) 
Huntington disease (HD), fragile X syndrome, and many others resulting from the accumulation of 
triplet repeats (CTG-CAG, CGG-CCG or GAA-TTC) in corresponding genes [9, 10]. Symptoms start to 
develop in carriers of the repeat as soon as a sufficient number of triplet copies are acquired. This 
number increases in successive generations due to somatic instability of the expanded sequence, 
leading to the unusual pattern of genetic anticipation, a phenomenon in which each generation 
shows earlier onset of the disease together with increasing severity of the symptoms [9, 10]. 
Despite great efforts in the last decade, there is still no cure for these disorders [6]; however, 
several treatment strategies are under development. Here, we discuss the most recently studied 
treatment approaches directed against nucleic acids, some of which have potential applications in 
future gene therapy of trinucleotide repeat expansion disorders. 
2. Materials and Methods 
This review was conducted through searches of scientific publications, review papers, books 
and theses available in the PubMed, B-On, SciELO, and Science Direct databases, as well as the 
libraries of O P´orto Medicine Faculty (FMUP) and Fernando Pessoa University. Searches were 
performed using the following keywords were: “treatment of trinucleotide repeat diseases”, 
“diseases of trinucleotide repeats”, “neurodegenerative disorders”, “spinocerebellar ataxia”, 
“Huntington disease”, “fragile X disease”, “myotonic dystrophy”, “Friedrich ataxia”, “fragile X-
associated ataxia”. 
3. Experimental Therapies Directed Against Triplet Repeats 
Development of selective therapeutic strategies is based on differences between normal and 
mutant transcripts in terms of repeat sequence length and assumed secondary structures [6]. 
The most promising approaches for possible treatments are aimed at lowering mutant protein 
synthesis by targeting DNA or RNA transcripts in cases of diseases where there is a gain-of-
function. 
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On the other hand, other strategies aimed at increasing expression of the wild-type gene by 
targeting DNA are under development for the treatment of genetic diseases resulting from 
decreased gene expression. 
The treatment approaches discussed here are divided in accordance with the target nucleic 
acid: RNA transcript or DNA. 
3.1. RNA-Targeting Strategies 
RNA-targeting has been developed using three main strategies directed against triplet RNA 
repeats: RNA interference (RNAi), antisense oligonucleotides (ASOs) or the use of splicing 
inhibitors. 
RNA Interference (RNAi). RNA interference (RNAi) is based on degradation of mutant 
transcripts since these RNA molecules bind to mRNA in the cytoplasm, leading to its degradation 
by the RNase enzyme, argonaute 2 [11]. 
These antisense reagents, together with antisense oligonucleotides, are known as “cutters” 
since they attach to complementary targets and induce their cleavage. 
In 2015, Bisset et al. [12] proposed this strategy as a promising therapeutic approach for 
genetic disorders involving gain-of-function. These researchers designed miRNA-based RNAi 
hairpins to target the mutant CUG expansion mRNA in a mouse model of myotonic dystrophy type 
1 (DM1). As a route to systemic gene therapy in mice, the RNAi expression cassettes were 
delivered by intravenous injection of recombinant adeno-associated viral vectors. A significant 
reduction in disease pathology in the muscles of treated mice was observed, together with 
reduced mutant mRNA levels and a decrease in myonuclear foci containing the mutant mRNA. It 
was concluded that RNAi has potential as a long-term therapy for DM1 and other dominant 
muscular dystrophies [12]. 
This methodology has also been used in studies of the treatment of Huntington disease. Harper 
et al. [13] demonstrated that RNAi directed against the mutant human htt gene, reduced 
huntingtin expression at both the mRNA and protein levels in cell cultures and HD mouse brain. 
Furthermore, delivery of adeno-associated virus constructs containing short hairpin RNAs that 
reduced htt gene expression resulted in improvements in the neuropathological changes 
associated with HD in a mouse model [13]. 
Franich et al. [14] used RNAi to target mutant htt gene expression mediated by virus vector 
delivery in HD transgenic mouse models. This strategy was shown to mediate a dramatic 
knockdown in mutant HD gene expression, preventing striatal neurodegeneration and 
concomitant motor behavioral impairment [14]. 
In a study of the safety of RNAi treatment in primates, McBride et al. [15] demonstrated that a 
45% reduction in rhesus htt gene expression did not induce motor deficits or neuronal 
degeneration. This study suggests that partial suppression of wild-type htt expression is well-
tolerated in the primate and further supports the use of RNAi as a therapy for HD [15]. 
Miniarikova et al. [16] evaluated two RNAi-based approaches for the treatment of HD. They 
observed total silencing of wild-type and mutant huntingtin (HTT) protein following RNAi-
mediated targeting of exon 1 of the htt gene. These researchers also used an allele-specific 
silencing strategy based on targeting the heterozygous single nucleotide polymorphism rs362331 
in exon 50 or rs362307 in exon 67, which are linked to mutant HTT [16]. They observed strong 
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allele-selective silencing of mutant HTT when targeting rs362331 both in vitro and in vivo [16]. This 
study showed that a single treatment provides a sustained reduction in HTT expression. 
RNAi has been proposed as a strategy for gene therapy of genetic disorders. As a good example 
of this approach, Keiser et al. [17] reported that spinocerebellar ataxia type 1 could be reversed by 
RNAi therapy. These researchers had previously shown that partial suppression of mutant ataxin-1 
gene expression following delivery of a single dose of virus could prevent the development of 
disease symptoms in a transgenic mouse model and a knock-in mouse model of the disease [18]. 
Their subsequent investigations then showed that RNAi not only prevented, but also reversed 
disease development when delivered after the onset of symptoms. In this study, a recombinant 
adeno-associated virus expressing an artificial miRNA targeting human ATXN1 mRNA was 
delivered at multiple doses in a mouse model of spinocerebellar ataxia type 1, before or after 
symptom onset [17]. 
Antisense Oligonucleotides (ASOs). Antisense oligonucleotides (ASOs) are complementary to 
mutant mRNAs, and thus hybridize with them, catalysing degradation of these transcripts by 
RNase H and consequently, leading to a reduction in coded protein levels [6]. 
Wheeler et al. [19, 20] observed that DM1 nuclear expansions are highly sensitive to antisense 
silencing. A transgenic mouse model of DM1 expressing human skeletal actin transcripts with the 
expansion (CUG)250 inserted in the 3′-UTR was used to show that it is possible to reverse changes 
observed in myotonic dystrophy. This was achieved by administration of a morpholino ASO, 
CAG25, which binds to CUGexp RNA and blocks its interaction with CUGexp-binding proteins [19]. 
The morpholino ASO was loaded into muscle fibers by intramuscular injection followed by in 
vivo electroporation. The muscular tissue was then examined 1–3 weeks later by fluorescence in 
situ hybridization using probes that hybridize to the CUG repeat or to sequences flanking the 
repeat. Injection of CAG25 caused a marked reduction in nuclear foci and a redistribution of 
CUGexp-binding proteins [19]. Moreover, these researchers obtained a rapid knockdown of CUGexp 
RNA in skeletal muscle in the DM1 mouse model by systemic administration of ASOs [20]. 
In the same way, Mulders et al. [21] reported the use of ASOs in a mouse DM1 cell model and 
DM1 patient cells. Cells were transfected with ASOs complexed with polyethyleneimine. A (CAG)7 
ASO silenced RNA expression of mutant myotonic dystrophy protein kinase and reduced the 
number of ribonuclear aggregates. The study also showed that direct administration of this ASO 
into the muscle of DM1 model mice caused a significant reduction in the level of toxic RNA [21]. 
Other researchers used ASOs containing modified nucleic acid residues, known as “gapmers”, 
to induce RNase H-mediated degradation of DM1 pathogenic transcripts [22]. Using RT-PCR to 
quantify the mutant transcript, this study showed selective knockdown of expanded CUG 
transcripts and consequent disruption of RNA foci both in cell culture and DM1 mouse models 
[22]. Furthermore, these researchers concluded that the combination of gapmers and morpholino 
ASOs has the potential to enhance the knockdown effect [22]. 
ASOs were also tested in the treatment of HD. Kordasiewicz et al. [23] observed a delay in 
disease progression following transient infusion of ASOs into the cerebrospinal fluid in a 
symptomatic HD mouse model. They also observed a sustained reversal of the disease phenotype 
that persisted longer than the huntingtin knockdown. Reduction of wild-type huntingtin, along 
with mutant huntingtin, produced the same sustained disease reversal. ASO infusion into non-
human primates had a similar effect, with an 80% reduction in huntingtin transcript levels 
observed using this strategy [23]. 
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Moreover, using an HD mouse model, Datson et al. [24] observed a reduction (15%–60%) in 
soluble and aggregated mutant HTT protein in the brains of mice following infusions of (CUG)7 
ASOs [24]. 
ASOs were also tested in the treatment of the neurodegenerative disorder spinocerebellar 
ataxia type-3. Evers et al. [25] attempted to remove the toxic polyglutamine repeat from the 
atazin-3 protein through antisense oligonucleotide-mediated exon skipping. This strategy 
produced a reduction in mutant ataxin-3 toxicity, while maintaining important functions of the 
wild-type protein. In vitro studies showed that exon skipping did not negatively impact the 
ubiquitin-binding capacity of ataxin-3 and no toxic properties of the novel truncated ataxin-3 
protein were detected in the in vivo tests [25]. These researchers used this strategy for skipping of 
exon 8 and 9, resulting in the removal of a central region of 88 amino acids in the ataxin-3 protein 
that contains several predicted cleavage sites and two ubiquitin-interacting motifs. In vitro studies 
showed that the truncated ataxin-3 protein did not show cellular toxicity but was unable to bind 
poly-ubiquitin chains, which may interfere with its normal de-ubiquitinating function. Therefore, 
these researchers concluded that skipping of exon 8 and 9 is not a viable therapeutic option 
for this disorder [26]. However, exon 10 skipping led to the formation of a truncated ataxin-3 
protein lacking the toxic polyglutamine expansion and retaining its ubiquitin-binding and cleavage 
function. These data suggested that exon 10 skipping is a promising therapeutic approach for 
spinocerebellar ataxia type 3 [27]. 
Splicing Inhibitors. Splicing inhibitors have been used in the treatment of spinal muscular 
atrophy, which results from deficiency of a protein required for the survival of motor neurons. This 
genetic disorder is caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. In 
the absence of this protein, neurons gradually die and patient’s muscles waste away, leading to 
death. Naryshkin et al. [28] discovered small-molecule drugs that increase synthesis of the missing 
protein by inhibiting the alternative splicing that leads to the generation of the truncated SMN 
protein and neuromuscular degeneration [28]. In mouse models of severe spinal muscular 
atrophy, administration of these compounds produced a marked improvement in muscle mass, 
motor function and survival [28]. These splicing modifiers may have therapeutic potential for 
patients with spinal muscular atrophy. 
Furamidine, a RNA CAG Binder. In Huntington disease, the mutant CAG-repeat RNA codes for 
neurotoxic polyglutamine proteins and can lead to a toxic gain-of-function by recruitment of RNA-
binding proteins. The link between these molecules induces aberrant HTT protein translation. 
Matthes et al. [29] identified a set of CAG repeat binders, one of which, furamidine, reduced the 
binding of huntingtin mRNA to several RNA-binding proteins in vitro [29]. Moreover, furamidine 
also decreased HTT protein levels in an HD cell line model [29]. However, this ligand, which can 
also bind to AU RNAs, CUG RNAs or even the DNA minor groove (AT), seems to bind the CAG-
repeat RNA in an unspecific manner and only when present in high concentrations. Thus, due to 
the high risk of off-target effects, furamidine is not a good candidate as an anti-HD drug. 
Nevertheless, this study shows that small molecules that mask RNA-protein interactions may be 
active against the mutant HTT protein [29]. 
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3.2. DNA Targeting Strategies 
In trinucleotide repeat diseases where there is a gain-of-function, targeting DNA to reduce 
protein expression represents a strategy for gene therapy. Several approaches are currently being 
tested, including the use of zinc finger proteins, clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated 9 (Cas9), and transcription activator-like effector nucleases 
(TALENs) as well as peptide nucleic acid (PNA)-peptide conjugates and locked nucleic acid (LNA) 
oligomers. 
The main advantage of the use of zinc finger proteins, TALENs or CRISPR/Cas9 is that these 
strategies allow the introduction of a double-stranded break at specific points in the DNA and 
thus, induce homology-directed repair [30]. These therapies have been tested for the insertion of 
a functional copy of an entire gene in a precisely targeted region. They can also be used to correct 
pathogenic mutations in situ [30]. 
In other triplet repeat diseases, such as Friedreich’s ataxia or spinal muscular dystrophy, the 
expanded repeat leads to a reduction in gene expression. In addition to the already described 
RNA-targeting strategies that can lead to increased gene expression, other methods have been 
developed to target DNA directly (for example ASOs), induce pharmacological modulation or 
inhibit histone deacetylase (HDAC). 
Zinc Finger Proteins. Zinc finger proteins can be targeted to specific DNA sequences and form a 
structural motif able to bind DNA, resulting in a reduction in protein synthesis. 
This strategy has been used to reduce levels of mutant huntingtin protein in HD animal models. 
For example, Garriga–Canut et al. [31] used long artificial zinc finger protein chains, designed to 
bind longer CAG-repeats more strongly than shorter repeats, in an HD mouse model. Based on the 
ability to recognize both poly-CAG and its complementary DNA strand, the designed zinc finger 
proteins recognized and bound to poly-5′-GC (A/T)-3′. These chains mediated preferential 
repression of target genes with longer CAG-repeats, when compared with shorter repeats 
following transient transfection and stable expression in various HD model cell lines. The stable 
expression of this zinc finger protein in an HD cell line model reduced chromosomal expression of 
the mutant gene at both the protein and mRNA levels (95% and 78% reduction, respectively) [31]. 
Wild-type gene expression was not affected by this strategy. Similar effects were observed 
following adeno-associated virus delivery in an HD mouse model in vivo. 
Similarly, Agustin–Parón et al. [32] designed a gene therapy strategy using a zinc finger 
transcription repressor that binds to expanded DNA CAG-repeats in the huntingtin gene. This 
study showed repression reaching 77% of the mutant huntingtin gene expression in whole brains 
of HD model mice [32]. A 48% repression was still observed 12 weeks after treatment and a 23% 
repression after 24 weeks, demonstrating that long-term effects can be achieved using this 
approach. However, since these proteins lead to the formation of non-native molecules, there is a 
risk increased immunogenicity and developing immune reactions [32]. 
Moreover, Kim and Kim [33] reported cytotoxicity, off-target effects and relatively low 
efficiency using zinc finger proteins [33]. 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated 9 
(Cas9). In the bacterial immune system, the clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated 9 (Cas9) gene-editing system can be used to introduce 
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double-stranded breaks in foreign DNA with high efficiency, low cytotoxicity, and relatively few 
off-target effects [34]. 
The Cas9 protein cuts target DNA, and the targeted sequence is repaired by gene-editing 
processes involving the non-homologous end-joining (NHEJ) and homology-directed repair (HDR) 
mechanisms. NHEJ results in the addition or deletion of nucleotides, whereas, HDR editing results 
in full DNA sequence restoration and can only be used when a homologous DNA sequence is 
present [35]. 
In HDR, targeted introduction of a donor sequence into the genome at the position of a 
CRISPR/Cas9-mediated DNA break is performed using genome-engineered constructs carrying 
homologous sequences [35]. 
In a recent study, this novel strategy was shown to induce the recovery of a normal phenotype 
in myogenic cells derived from fibroblasts of patients with myotonic dystrophy type 1 [36]. With 
the aim of eliminating the toxic mutant repeats, CRISPR/Cas9 facilitated removal of the repeat 
expansions, therefore, preventing nuclear foci formation and splicing alterations [36]. Compared 
with previously described strategies, this study demonstrated the advantage of this approach in 
that affected cells permanently reverted to the normal phenotype; however, off-target activity 
was observed [36]. Subsequent studies focused on improvement of the targeting specificity and 
adjustable expression of Cas9 nuclease, which are critical for therapeutic application of this 
strategy, since genome editing leads to permanent modifications. 
Pinto et al. [37] tested the hypothesis that deactivation of the Cas9 enzyme impedes 
transcription across expanded microsatellites in DM1 cells. Systemic delivery of dCas9/gRNA by 
adeno-associated virus led to a reduction in mutant RNA and decreased myotonia [37]. These 
results indicate that transcription of microsatellite repeat-containing RNAs is more sensitive to the 
action of Cas9 than transcription of other RNAs, making it a potential strategy for therapeutic 
intervention. 
Permanent inactivation of the Huntington disease mutation in fibroblasts of a patient was also 
achieved by Shin et al. using this approach [38]. In this study, the use of haplotype-specific 
CRISPR/Cas9 was demonstrated to inactivate the mutant HD allele. Two CRISPR/Cas9 guide RNAs 
that depend on protospacer-adjacent motif sites resulting from single nucleotide polymorphism 
alleles on the mutant chromosome were used to selectively excise a region of DNA (approximately 
44 kb) spanning the promoter region, transcription start site, and the CAG expansion mutation of 
the mutant htt gene, resulting in complete inactivation of the mutant allele without changes in the 
wild-type allele [38]. This prevented the formation of mutant HTT mRNA and protein, 
unequivocally indicating permanent mutant allele-specific inactivation of the HD mutant allele [38]. 
Potentially, this strategy could be used as gene therapy for disorders with diverse disease 
haplotypes, supporting precision medicine by inactivation of gain-of-function mutations. 
Moreover, a recent study described the development of a programmable CRISPR system 
capable of specifically visualizing and eliminating toxic RNAs resulting from 
microsatellite repeat expansions present in DNA [39]. Researchers observed reversal of hallmark 
features of disease, including elimination of RNA foci, in the cells of patients of affected by each of 
the studied diseases (DM1, DM2, C9-ALS, polyglutamine diseases) [39]. 
Several studies compared the mutagenic rates of CRISPR/Cas9, zinc finger proteins and TALENs. 
Kim and Kim [33] observed similar mutation rates for all methods, while Auer and Del Bene [35] 
showed CRISPR/Cas9 mutation rates ranging between 42% and 100% compared with a mutation 
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rate of 33% for TALENs [35]. In another study, mutation rates of 11% for TALENs and 76% for 
CRISPR-Cas9, were recorded for the same gene [40]. 
In the same way, He et al. [41] observed more efficient targeted genomic deletions together 
with more precise re-joining of breakpoint junctions induced by CRISPR/Cas9 compared with the 
use of TALENs. In comparisons of the ability to edit an integrated gene, CRISPR/Cas9 was found to 
be superior for targeted genomic deletions, while TALENs outperformed CRISPR/Cas9 for 
stimulation of concurrent HDR at proximal sites within a single gene [41]. 
Kolli et al. [42] reported a relatively low rate of HDR using CRISPR/Cas9 and other studies 
suggest that the rate of HDR is dependent on gRNA concentration and Cas9 protein availability [43, 
44]. 
A recent study showed similar behavior of heterodimeric zinc finger proteins 
and CRISPR/Cas9 for homology-directed gene knock-in strategies (88% and 83%, respectively, of 
the donors inserted in the target locus), whereas homodimeric zinc finger proteins showed only 
45% on-target insertions [45]. 
Although CRISPR/Cas9 has enormous potential for gene therapy and genome editing 
applications, some challenges need to be overcome before this approach can be used for the 
treatment of human diseases. One of the most important challenges, is the reduction of off-target 
effects. Since the gRNA of the CRISPR/Cas9 targeting system is only 17–24 bp in length, there is a 
high chance that the selected sequence exists elsewhere besides the target regions. Moreover, 
sequences with small changes to the target gRNA sequence might exist in the genome and can 
cause mis-targeting. However, several studies suggest that Cas9 can withstand mismatches, and is 
dependent on the distribution and number of mismatched nucleotides [46-48]. Kim and Kim [33] 
reported that off-target effects of CRISPR/Cas9 system can be reduced by altering the Cas9 
enzyme to act as a nickase, capable of cleaving only one target DNA strand [33]. 
Transcription Activator-Like Effector Nucleases (TALENs). Like zinc finger nucleases and 
CRISPR)/CRISPR-Cas9, transcription activator-like effector nucleases (TALENs) are engineered 
nucleases that have been widely used to generate double-strand DNA breaks (DSBs) to increase 
the efficiency of standard homologous recombination. Mosbach et al. [49] showed that a TALEN-
induced double-stranded break was very efficient at contracting expanded CTG repeats in yeast. 
This study showed that, following the TALEN-induced double-strand break, single-strand annealing 
occurred between both sides of the repeat tract, leading to repeat contraction [49]. These results 
implicate TALENs as a promising strategy for gene therapy of trinucleotide repeat disorders; 
however, although TALENs have a higher efficiency than zinc finger proteins, it requires huge 
resources, and delivery into cells is often a challenge [33, 34]. 
Peptide Nucleic Acid (PNA)-Peptide Conjugates and Locked Nucleic Acid (LNA) Oligomers. An 
important issue in therapy directed against triplet repeats is the need for gene and allele 
selectivity. Although numerous mRNAs in the human transcriptome contain triplet repeats, the 
specific inhibition of mutant gene expression by targeting certain repeat regions is a promising 
therapy strategy for these types of diseases [6]. 
Agents have been developed to distinguish between RNA hairpin structures formed by wild-
type and mutant RNAs based on differences in length and consequently, in stability. 
Hu et al. [50] used peptide nucleic acid (PNA)-peptide conjugates and locked nucleic acid (LNA) 
oligomers for specific reduction of mutant huntingtin gene expression [50]. PNAs, which are a 
class of DNA/RNA mimic with an uncharged amide backbone, are advantageous as agents for 
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binding complementary RNA sequences due to the lack of charge-charge repulsion of RNA/DNA or 
RNA/RNA duplexes. This results in an increase in the affinity of PNA hybridization and recognition 
of target sequences. PNAs can be delivered to live cells and are resistant to proteases and 
nucleases, which makes them promising therapeutic agents. PNA oligomers hybridize to DNA and 
RNA in a sequence-specific manner. Kiliszek et al. [51] demonstrated the high sequence-specificity 
of PNAs in studies of the crystal structures of RNA-PNA duplexes and a PNA-PNA duplex containing 
mismatches. Using this technique, only fully complementary RNA-PNA duplexes could be 
obtained, while co-crystallization trials of mismatching RNA with PNA resulted only in crystals of 
mismatched PNA-PNA [51]. This sequence selectivity is a desirable property for antisense 
therapeutic strategies against trinucleotide repeat expansion diseases since it will allow inhibition 
of mutant gene expression without interfering with the wild-type gene. 
On the other hand, LNAs are RNA analogs containing a methylene bridge between the 2'-
oxygen and 4'-carbon of the ribose. This bridge reduces the conformational flexibility of ribose and 
confers outstanding affinity in complementary hybridization. Hu et al. [50] observed that LNAs, as 
well as previously described PNAs, can confer potent allele-selective inhibition of mutant 
huntingtin gene expression [50]. In the same way, Rué et al. [52] observed that a LNA-modified 
antisense oligonucleotide complementary to the CAG-repeat (LNA-CTG) preferentially bound to 
mutant htt gene without affecting wild-type HTT mRNA or protein levels. Furthermore, these 
researchers observed that this strategy promotes neuroprotection in a mouse model of HD by 
blocking the detrimental activity of CAG-repeats in the htt gene [52]. 
Antisense Oligonucleotides (ASOs). ASOs have also been used to increase gene expression in 
cell lines derived from patients with Friedreich’s ataxia and spinal muscular dystrophy [53, 54]. The 
proposed mechanism by which ASOs increase gene expression involves the binding of these 
compounds to the expanded repeat and blockade of the expanded RNA, which inhibits recognition 
of DNA, prevents R-loop formation and allows more gene expression. 
A study by Li et al. [53] demonstrated that ASOs and dsRNAs can activate frataxin protein 
expression in Friedreich’s ataxia patient-derived cell lines that possess varied numbers of GAA 
repeats. Increased frataxin protein expression was achieved by ASOs incorporating diverse 
chemical modifications [53]. 
Using the same strategy, Corey et al. [54] showed the nusinersen (Spinraza), a recently 
approved antisense oligonucleotide drug, can be used for the treatment of spinal muscular 
atrophy [54]. 
Pharmacological Modulation during Somatic Cell Reprogramming. Another recently evaluated 
strategy was based on the hypothesis that the epigenetic modifications close to GAA repeats 
present in Friedreich's ataxia can be reversed by pharmacological modulation during somatic cell 
reprogramming [55]. In this study, researchers induced the generation of pluripotent stem cells by 
reprogramming Friedreich's ataxia fibroblasts in the presence of various small molecules that 
target DNA methylation as well as histone acetylation and methylation. Treatment of these stem 
cells with two compounds (sodium butyrate and Parnate [tranylcypromine]), led to increased 
expression of the frataxin gene, which persisted for several passages [55]. However, they observed 
that prolonged culture of those epigenetically modified cells resulted in progressive expansion of 
triplet repeats and a consequent decrease in gene expression. 
Histone Deacetylase (HDAC) Inhibitors. Evidence indicates that transcriptional dysregulation is a 
contributor to the molecular pathogenesis of Huntington disease. For this reason, histone 
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deacetylase (HDAC) inhibitors have been tested in the treatment of Huntington disease, with the 
aim of correcting transcriptional dysregulation through chromatin modification. These inhibitors 
prevent removal of acetyl groups from histones. As a result, DNA assumes a more relaxed 
structure, allowing access of transcription factors to DNA and consequently, activating gene 
transcription. 
Hockly et al. [56] explored the therapeutic potential of HDAC inhibitors by conducting 
preclinical trials with a potent HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), in a mouse 
model of HD. These researchers showed that this molecule crosses the blood-brain barrier and 
increases histone acetylation in the brain. Furthermore, this treatment dramatically improved 
motor impairment of HD mice [38]. Moreover, Mielcarek et al. [57] demonstrated that SAHA also 
promotes the degradation of several classes of HDACs at the protein level in various cancer cell 
lines and in the cortex and brain stem in mouse models. 
4. Conclusion 
Trinucleotide repeat expansions are responsible for the development of several genetic 
disorders. The instability of these repeats leads to their expansion and to the accumulation of 
increasing numbers of triplets from one generation to the next. This results in the phenomenon of 
anticipation, which is characteristic of triplet diseases, where development of symptoms occurs 
earlier in each generation. 
To date, there is no cure for this type of disorder, although several possible treatment 
strategies are under investigation. The goal of most available treatments is to relieve symptoms 
and provide patients with a better life quality. However, the possibility of a cure for affected 
patients should be explored. Therefore, several approaches directed against DNA or RNA are 
under development based on the potential of these approaches to achieve prolonged, or even 
permanent, reversal of symptomatology. 
Some of the approaches described interfere not only with the mutant gene or mRNA, but also 
with the wild-type, and for this reason might lead to dysregulation of gene expression. To avoid 
further adverse effects, it is essential that the treatment strategy is directed specifically to the 
mutant nucleic acids. 
Moreover, several of the discussed strategies allow the removal of the repeat expansion, 
leading to total recovery of the wild-type phenotype. These treatment approaches offer the 
potential for the establishment of a cure for trinucleotide repeat diseases. 
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